Switch theme
Sign up to access all valuation multiples
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system.
1993
94
LTM Revenue n/a
LTM EBITDA n/a
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BB Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BB Biotech achieved revenue of -$226M and an EBITDA of n/a.
BB Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BB Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | -$397M | -$226M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | n/a | n/a | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$458M | -$405M | XXX | XXX | XXX |
| Net Margin | 115% | 179% | XXX | XXX | XXX |
| Net Debt | $398M | $408M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BB Biotech's stock price is CHF 26 (or $30).
BB Biotech has current market cap of CHF 1.4B (or $1.6B), and EV of CHF 1.7B (or $1.9B).
See BB Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.6B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BB Biotech has market cap of $1.6B and EV of $1.9B.
BB Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BB Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BB Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.9B | XXX | XXX | XXX |
| EV/Revenue | -8.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -7.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBB Biotech's NTM/LTM revenue growth is n/a
BB Biotech's revenue per employee for the last fiscal year averaged -$2.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, BB Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BB Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BB Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -43% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | -$2.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | -1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | -2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | -3% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BB Biotech acquired XXX companies to date.
Last acquisition by BB Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . BB Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BB Biotech founded? | BB Biotech was founded in 1993. |
| Where is BB Biotech headquartered? | BB Biotech is headquartered in Switzerland. |
| How many employees does BB Biotech have? | As of today, BB Biotech has 94 employees. |
| Is BB Biotech publicy listed? | Yes, BB Biotech is a public company listed on SWX. |
| What is the stock symbol of BB Biotech? | BB Biotech trades under BIOEE ticker. |
| When did BB Biotech go public? | BB Biotech went public in 2012. |
| Who are competitors of BB Biotech? | Similar companies to BB Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of BB Biotech? | BB Biotech's current market cap is $1.6B |
| What is the current revenue growth of BB Biotech? | BB Biotech revenue growth between 2023 and 2024 was -43%. |
| Is BB Biotech profitable? | Yes, BB Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
